September

/
/
September
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

London, UK; 26 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing…

Your Feedback Requested: Parents/Caregivers Medical Cannabis Survey

At the Child Neurology Foundation (CNF), our mission is to serve as a collaborative center of education and support for children living with neurologic conditions…

PCORI Annual Meeting Scholarships

The 2016 PCORI Annual Meeting is taking place in November in the greater Washington, D.C. area, and we’re offering scholarships to help patients, caregivers, and…

Start typing and press Enter to search

Shopping Cart